Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)

被引：0
|
作者：
Herzberg, B. [1 ]
Johnson, M. [2 ]
Kim, C. G. [3 ]
Tolcher, A. [4 ]
Rodon, J. [5 ]
Mantia, C. [6 ]
Liu, J. [7 ]
Tripathi, A. [8 ]
Rodriguez, L. Paz-Ares [9 ]
Rouge, T. De la Motte [10 ]
Choi, C. M. [11 ]
Han, J. Y. [12 ]
Kwei, L. [13 ]
Liu, E. [14 ]
Sachdev, J. [14 ]
O'Quigley, M. [14 ]
White, M. [15 ]
Beaupre, D. [16 ]
Kim, H. R. [17 ]
机构：
[1] Columbia Univ, Dept Hematol & Oncol, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[2] Sarah Cannon Res Inst, SCRI Dev Innovat Div, Nashville, TN USA
[3] Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[4] NEXT Oncol, Clin Res, San Antonio, TX USA
[5] MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA
[6] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Ctr Canc Therapeut Innovat, Dept Med Oncol, Boston, MA USA
[7] St Vincents Hosp Sydney, Med Oncol, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[9] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[12] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[13] IDEAYA Biosci, Biometr, San Francisco, CA USA
[14] IDEAYA Biosci, Clin Dev, San Francisco, CA USA
[15] IDEAYA Biosci, Res, San Francisco, CA USA
[16] IDEAYA Biosci, Clin Dev, San Diego, CA USA
[17] Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501LBA
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [1] The MAT2A inhibitor IDE397: a novel combination backbone for urothelial cancer subjects with MTAP deficiency
    Neilan, Claire L.
    Fischer, Marcus M.
    Garbett, Damien
    Rao, Arjun A.
    Mandal, Mili
    White, Michael A.
    Sachdev, Jasgit C.
    CLINICAL CANCER RESEARCH, 2024, 30 (10)
  • [2] Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
    Doebele, Robert
    Horn, Leora
    Spira, Alexander
    Piotrowska, Zofia
    Costa, Daniel
    Neal, Joel
    Reichmann, William
    Kerstein, David
    Li, Shuanglian
    Janne, Pasi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1072 - S1073
  • [3] A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)
    Meric-Bernstam, Funda
    Gordon, Michael
    Tykodi, Scott
    Lam, Elaine
    Vaishampayan, Ulka
    Chaves, Jorge
    Nikolinakos, Petros
    Fan, Alice
    Lee, Richard
    McDermott, David
    Shapiro, Geoffrey
    Gandhi, Leena
    Tawbi, Hussein
    Bhatia, Shailender
    Muigai, Lucas
    Jenkins, Yonchu
    Whiting, Sam
    Voss, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [4] Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
    Antonia, S. J.
    Brahmer, J. R.
    Khleif, S.
    Balmanoukian, A. S.
    Ou, S-H. I.
    Gutierrez, M.
    Kim, D-W.
    Kim, S-W.
    Ahn, M-J.
    Leach, J.
    Jamal, R.
    Jaeger, D.
    Jerusalem, G.
    Jin, X.
    Gupta, A.
    Antal, J.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Yasenchak, C.
    Nackaerts, K.
    Awada, A.
    Gadgeel, S. M.
    Hellerstedt, B.
    Perry, M. C.
    Richards, D.
    Yang, C. H.
    Scheffold, C.
    Lara, P. N., Jr.
    EJC SUPPLEMENTS, 2010, 8 (07): : 126 - 126
  • [6] Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Plummer, R.
    Cook, N.
    Arkenau, T.
    Melear, J.
    Redfern, C.
    Spira, A. I.
    Chung, K.
    Haddad, T.
    Ramalingam, S. S.
    Wesolowski, R.
    Dean, E.
    Goddemeier, T.
    Falk, M.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 519 - 519
  • [7] Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
    Bhalla, Sheena
    Fattah, Farjana J.
    Ahn, Chul
    Williams, Jessica
    Macchiaroli, Alyssa
    Padro, Jonathan
    Pogue, Meredith
    Dowell, Jonathan E.
    Putnam, William C.
    McCracken, Nigel
    Micklem, David
    Brekken, Rolf A.
    Gerber, David E.
    LUNG CANCER, 2023, 182
  • [8] JAVELIN MEDLEY VEGF: PHASE 2 STUDY OF AVELUMAB plus AXITINIB IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) OR TREATMENT NAIVE, CISPLATIN-INELIGIBLE UROTHELIAL CANCER (UC)
    Galffy, Gabriella
    Lugowska, Iwona
    Poddubskaya, Elena
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Han, Ji-Youn
    Su, Wu-Chou
    Hauke, Ralph
    Dyar, Stephen
    Lee, Dae Ho
    Serwatowski, Piotr
    Estelles, David Lorente
    Holden, Viran
    Kim, Yu Jung
    Vladimirov, Vladimir
    Horvath, Zsolt
    Ghose, Abhimanyu
    Goldman, Allison
    di Pietro, Alessandra
    Wang, Jing
    Murphy, Danielle
    Laskov, Mikhail
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A171 - A172
  • [9] Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
    Paulus, Astrid
    Cicenas, Saulius
    Zvirbule, Zanete
    Paz-Ares, Luis G.
    Awada, Ahmad
    Garcia-Ribas, Ignacio
    Losic, Nedjad
    Zemaitis, Marius
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer
    Patel, J.
    Spira, A.
    Stevenson, J.
    Chen, H.
    Baik, C.
    Gordon, S.
    Henry, J. T.
    Ahluwalia, M.
    Barve, M.
    Huang, C.
    Edenfield, J.
    Johnson, M.
    Eathiraj, S.
    Hajdenberg, J.
    Yurasov, S.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S657 - S657
12345